Formularies can change, so its essential to review them annually
The conversion guidance that exists for transitioning between other GLP-1 agonists can provide some framework for thinking about dosing during transitions, though no specific tirzepatide-to-retatrutide conversion protocol has been established in clinical literature
Competitive athletes in sports with active anti-doping programs should be aware that Thymosin Beta-4 analogs appear on the WADA Prohibited List under S2
Gatchalian, program manager, Addiction Recovery Research Center, Fralin Biomedical Research Institute at VTC Amber Kelly, graduate student, Translational Biology, Medicine, and Health Graduate Program Alexandra DiFeliceantonio, assistant professor, Fralin Biomedical Research Institute at VTC, associate director, Center for Health Behaviors Research